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Abstract
Background: Balo’s concentric sclerosis (BCS) is a rare condition characterized
by concentrically layered white matter lesions. While its pathogenesis is
unknown, hypoxia-induced tissue injury and chemotactic stimuli have been
proposed as potential causes of BCS lesion formation. BCS has been suggested
to be a variant of multiple sclerosis (MS). Here, we aimed to elucidate similari-
ties and differences between BCS and MS by describing lesion morphology and
localization in high-resolution 7 Tesla (7 T) magnetic resonance imaging (MRI)
scans. Methods: Ten patients with Balo-type lesions underwent 7 T MRI, and
10 relapsing remitting MS patients served as controls. The 7 T MR imaging
protocol included 3D T1-weighted (T1w) magnetization-prepared rapid gradient
echo, 2D high spatial resolution T2*-weighted (T2*w) fast low-angle shot and
susceptibility-weighted imaging. Results: Intralesional veins were visible in the
center of all but one Balo-type lesion. Four Balo-type lesions displayed inhomo-
geneous intralesional T2*w signal intensities, which are suggestive of microhem-
orrhages or small ectatic venules. Eight of 10 BCS patients presented with 97
additional lesions, 36 of which (37%) had a central vein. Lesions involving the
cortical gray matter and the U-fibers were not detected in BCS patients. Con-
clusion: Our findings support the hypothesis that BCS and MS share common
pathogenetic mechanisms but patients present with different lesion phenotypes.
Introduction
Prior to the availability of high-resolution magnetic reso-
nance imaging (MRI), Balo’s concentric sclerosis (BCS)
was diagnosed by the presence of large, inflammatory
lesions with concentric rings within the brain’s white
matter obtained via autopsy or biopsy.1–3 BCS was
believed to be a destructive focal neuroinflammatory
condition and entailed a devastating prognosis.1,4,5 With
the increasing use of MRI, diagnosis of BCS is now gener-
ally based on radiographic findings and identified already
early in the course of the disease.1,4
Characteristic MRI features of Balo-type lesions
comprise circular layers of alternating signal intensity on
T1- or T2-weighted (T1w or T2w, respectively) images.
1,2,6
Lesions are typically located within the cerebral white
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matter, the basal ganglia, pons, cerebellum, and the spinal
cord, while they usually spare the U-fibers.1,2,7,8
Clinical symptoms of BCS are described as (sub)acute
onset of hemiparesis, hemianopia, or hemihypoesthesia,
but also headache, encephalopathic symptoms, and sei-
zures.4,6,7 BCS patients treated with immunomodulatory
and immunosuppressive drugs show recovery from symp-
toms and prolonged survival, similar to multiple sclerosis
(MS).1,4,6–8 In light of an overlap of neuropathological
and clinical findings,1,3,8,9 the question arises as to
whether BCS is a rare variant of MS, a disease entity of
its own, or a clinical and radiological phenotype compris-
ing different disease entities. Ultrahigh-field MRI at
7 Tesla (7 T) benefits from high spatial resolution and
enhanced susceptibility effects that improve the visualiza-
tion, detection, and morphological description of inflam-
matory brain lesions.10–13 More precisely, in T2*w MRI, a
central vessel can frequently be depicted within MS
lesions, and the presence of a central vessel is believed to
be typical for MS lesions.10,11,13 Given the unresolved
nosologic association of BCS with MS, we set out to
investigate the similarities and differences of BCS and MS
lesions via high spatial resolution 7 T MRI. We did so in
a prospective observational study of 10 BCS patients and
10 MS patients to investigate whether ultrahigh field
lesion characteristics that are considered typical of MS are
also present in BCS patients. Moreover, we compared
additional clinical and paraclinical findings in BCS and in
MS patients, including the course of the disease (re-scan
and telephone interview), and testing for autoantibodies
against aquaporin-4 (AQP4), and myelin oligodendrocyte
glycoprotein (MOG-IgG) that have been reported in
patients with large or tumefactive brain lesions.14–17
Methods
Study participants
Ten BCS patients were prospectively recruited from the
neuroimmunology outpatient clinics of the Experimental
and Clinical Research Center and the NeuroCure Clinical
Research Center at Charite – Universit€atsmedizin Berlin.
The patients had been referred to Charite for obtaining a
second opinion. The study design is outlined and detailed
in Figure 1. Inclusion criteria were age 18–65 years and
diagnosis of BCS that was based on conventional MRI find-
ings (at least two hyperintense areas separated by one
hypo-/isointense rim on T2w images)
1,3,8,18–20 and con-
firmed by histopathological analyses in three patients. The
only exclusion criterion was contraindication to undergo
7 T MRI. For comparison, the 10 best-matching patients
regarding disease duration, age, and sex with relapsing
remitting MS (RRMS) for whom 7 T MRI scans were
available were selected from the NeuroCure neuroimaging
database as controls. The study was conducted in confor-
mity with the Declaration of Helsinki and approved by the
ethics committee of Charite – Universit€atsmedizin Berlin.
All participants provided written informed consent.
Clinical and paraclinical characterization
Medical records of the BCS patients were used to obtain
data on the initial clinical presentation, disability measured
through the Expanded Disability Status Scale (EDSS),21
CSF oligoclonal bands, immunomodulatory treatment as
well as disease duration. In addition, BCS patients under-
went clinical examination and EDSS assessment at the time
of 7 T MRI (30 days). Disease duration was defined as
time between first symptoms (onset) and 7 T MRI. The
follow-up period started with the completion of the 7 T
examination and ended with a telephone interview
(Fig. 1). In order to investigate a possible association with
neuromyelitis optica spectrum disorders or anti-MOG
antibody-associated encephalomyelitis, serum samples
from all 10 BCS patients were tested for serum AQP4- and
MOG-IgG at the University Hospital Heidelberg14 using a
cell-based assay (CBA).14 CBA employed human embry-
onic kidney 293 cells transfected with human full-length
MOG as previously described14; nontransfected cells were
used as control substrate.
MR imaging acquisition
Ultrahigh-field MR images of BCS and RRMS patients were
acquired using a 7 T Siemens whole-body scanner (Magne-
tom, Siemens, Erlangen, Germany) and a 24-channel recei-
ver head coil (Nova Medical, Wilmington, MA) equipped
with a birdcage volume coil for transmission. The imaging
protocol included a two-dimensional T2*w fast low-
angle shot sequence (T2*w, FLASH, TE = 25 msec;
TR = 1820 msec; spatial resolution = 0.5 9 0.5 9 2 mm3,
supratentorial coverage), a three-dimensional T1-weighted
magnetization-prepared rapid gradient echo sequence
(T1w, MPRAGE, TE = 2.98 msec; TR = 2300 msec; inver-
sion time [TI] = 900 msec; spatial resolution = 1.0 9
1.0 9 1.0 mm3, whole-brain coverage), a three-dimen-
sional fluid-attenuated inversion recovery sequence
(FLAIR, TE = 398 msec; TR = 8010 msec; TI = 2150
msec, spatial resolution = 1.0 9 1.0 9 1.0 mm3), and a
three-dimensional gradient echo flow-compensated suscep-
tibility-weighted imaging sequence (SWI, TE = 14 msec,
TR = 25 msec, flip angle = 12°; spatial resolution =
0.5 9 0.5 9 1.0 mm3, supratentorial coverage) that yields
magnitude, phase, and reconstructed SW images.
In addition, a very high-resolution 2D T2*w FLASH
sequence (TE = 25 msec; TR = 1820 msec; spatial
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Figure 1. Overview. A timeline of the overall study design (top) is displayed in addition to clinical and paraclinical findings of all individual
patients with Balo concentric sclerosis (bottom). The overall study design graphic represents mean time intervals between the single time points.
Patients were recruited in the outpatient clinic of the Charite – Universit€atsmedizin Berlin after the diagnosis of Balo concentric sclerosis. Three
patients with Balo concentric sclerosis underwent biopsy and/or surgical resection prior to study enrollment. Two patients had relapses during the
follow-up period (asterisks). 7 T, 7 Tesla MRI; 3 T, 3 Tesla MRI.
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resolution = 0.2 9 0.2 9 2 mm3) was done in nine
patients with Balo-type lesions. For information on the
3 T MRI protocol please see Data S1.
Image analysis
The 7 T MR images were analyzed by two experienced
investigators (Julia Wanner, Tim Sinnecker) who did not
have any knowledge of clinical details (EDSS, age, sex) in
consensus reading, using the OsiriX software package
(OsiriX Foundation, Geneve, Switzerland, version 3.8.1).
BCS lesion morphology, including the existence of a cen-
tral venous vessel, a T2*w hypointense rim, and intrale-
sional T2*w signal alterations, was assessed in consensus
reading. A central vein in a Balo-type lesion was defined
as a vein that runs in equidistance to the border through
the inner circle of a Balo-type lesion.
In addition, the number of additional non-Balo lesions
in BCS patients was determined. Hereby, a brain lesion
was defined as a hyperintense area of at least three voxels
on FLAIR and T2*w images. The “central vein sign” was
assessed in these lesions according to NAIMS criteria in
consensus reading.22 In addition, the involvement of U-
fibers, the existence of Dawson’s fingers, and Barkhof cri-
teria were assessed.23
The analysis of the 3 T MR images included the assess-
ment of the MRI part (dissemination in space and time)
of the 2010 MS diagnostic panel criteria,24 based on 3 T
MR image taken at the beginning of the study. The fol-
low-up 3 T MRI images were analyzed with regard to
newly developed lesions and whether a patient met posi-
tive MS diagnostic criteria.24
Statistical analysis
A Mann–Whitney U-test was used to detect differences
between MS and BCS patients. P < 0.05 were considered
statistically significant.
Results
Study participants
Ten patients with Balo-type lesions detected by MRI at dis-
ease onset were included (nine female). Mean age was 35.2
(SD = 7.9 years, range 27–49 years), and the mean disease
duration – from disease onset to acquisition of the 7 T
MR image – was 20.6 months (SD = 24.4 months, range
3–67 months). BCS patients presented with a median
EDSS of 3.75 (range 2.0–4.0). The median clinical follow-
up was 31.0 months (range 21–38 months).
As a control group, 10 patients with relapsing–remit-
ting MS (RRMS) with comparable sex and age
distribution and EDSS scores were included (nine female;
mean  SD age 31.7  6.8 years, range 23–43 years,
P = 0.28; mean  SD disease duration 31.2 
34.3 months, range 2–113 months, P = 0.53; median
EDSS 1.5, range 0–2.0). More clinical details of the BCS
patients are presented in Table 1 and Figure 1.
Clinical findings in patients with Balo-type
lesions
Hemiparesis and/or hemihypoesthesia were the most fre-
quent symptoms at disease onset (n = 7) in BCS patients.
Eight of 10 patients showed an acute onset of symptoms
within hours to maximum symptom development, while
all 10 MS patients exhibited a subacute onset within days
to maximum symptom development. The majority of
BCS patients (n = 7) had no further relapses until the
end of observation, whereas three patients had relapses
(Table 3). There was no difference in age (P = 0.67), gen-
der (P = 0.83), disease duration (P = 1), and median
duration until the follow-up examination (P = 1) between
BCS patients with or without relapses. None of the BCS
patients reported neurological symptoms prior to the
symptomatic BCS lesion. All BCS patients received
methylprednisolone pulse therapy as an acute relapse
treatment at onset. In seven out of 10 patients, symptoms
were mitigated during methylprednisolone pulse therapy
(Table 1). Plasmapheresis was done in two patients.
Symptoms in these two patients incompletely recovered
during plasmapheresis. Cyclophosphamide cycles and
immunoglobulin therapy was given to one patient and
had no clinical effect. After the relapse therapy, treatment
regimens of BCS patients comprised immunomodulation
with glatiramer acetate (n = 3), interferon beta-1a
(n = 1), dimethyl fumarate (n = 3), natalizumab (n = 2)
as well as immunosuppression with cyclophosphamide
and subsequently azathioprine (n = 1) (Table 1). Relapses
during treatment are summarized in Table 3.
Lesion morphology of Balo-type lesions in
7 Tesla MRI
MR imaging findings are presented in Figure S1 and
summarized in Table 2. Lesion morphology at the time
of the 7 T MR imaging was partially concealed in three
patients due to surgical resection or biopsy. MR imag-
ing before biopsy or surgical resection is shown in Fig-
ure S2. All but the two partially resected Balo-type
lesions had characteristic lesions with concentric rings
on 7 T MR images (Fig. 2, Fig. S1). The rim thickness
varied across subjects: Four patients had rather thick
rims of more than 0.5 cm, and four patients had rims
smaller than 0.5 cm (Fig. S3). In greater detail, T2*w
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and SWI hypointense rim-like structures were regularly
observed at the border between T2*w and FLAIR hyper-
intense areas (n = 8). These T2*w and FLAIR hyperin-
tense areas corresponded to T1w hypointense lesion
areas. In one Balo-type lesion, brain tissue in-between
T2w hyperintense rims layers was characterized by T2*w
and T1w gray-scale intensity values similar to normal
appearing white matter (Fig. S4) as reported previ-
ously.25 In addition, lesions in four out of 10 BCS
patients (patients #1, #4, #5, and #7) had an inhomoge-
neous intralesional T2*w signal distribution, which is
suggestive of microhemorrhages or small ectatic venous
vessels within the lesions (Fig. 3). All Balo-type lesions
(n = 10) had spatial contact to the lateral ventricles and
the periventricular white matter preserving cortical areas
or U-fibers.
Central veins within Balo-type lesions
A distinct venous vessel was clearly visible in the center of
seven Balo-type lesions (Fig. 2), and not detectable in one
Balo-type lesion. In two BCS patients, the central vein
sign was not analyzable due to surgical resection.
Comparison between non-Balo lesions in
BCS patients and RRMS controls
Next, we compared imaging findings between non-Balo
lesions in the BCS group and brain lesions in the 10
matched RRMS patients.
In the BCS group, 97 non-Balo lesions were identified
in eight of 10 patients (Table 2). In the RRMS control
group, a total number of 204 lesions (median 5  29
lesions per patient, range 1–93) were analyzed.
First, the existence of a central vein was analyzed in
these lesions. In BCS, 36 of the 97 (37%) non-Balo lesions
were encircled around a central vein that was visible on
T2*w images (Fig. 4). The median proportion of lesions
with a central vein in additional non-Balo lesions per
patient was 42% (range 0–100%). More specifically, four
BCS patients were characterized by a proportion of at least
40% of lesions with a central vein (patients #2, #3, #9,
#10). In two additional BCS patients (patients #1, #8) a
clearly visible central vein was evident in one of three non-
Balo lesions. The central vein sign was detectable in less
than 40% of lesions and thus considered negative in BCS
patient #6 (the proportion of lesions with a central vein
was 24%). Patients #4 and #7 had no non-Balo lesions at
all. In patient #5, a vein was found in the center of two of
four lesions, but the lesions did not follow the course of
the vein.
In the control group, nine of 10 RRMS patients had at
least 40% or more lesions with a central vein (156 of 204
lesions [=77%], median 4.0 lesions per patient, range
0–77).
Second, U-fiber involvement and the existence of corti-
cal lesions were assessed. Cortical lesions or involvement
of U-fibers were absent in all BCS patients. By contrast,
two RRMS patients exhibited cortical gray matter lesions
(six of 204 lesions, 3%), and an involvement of U-fibers
was present in four RRMS patients.
In addition, Dawson’s finger-shaped lesions were found
in three of 10 BCS patients (patients #1, #3, #8; Fig. 4),
and eight of 10 RRMS patients.
Spinal cord MRI and follow up at 3 T
About nine BCS patients underwent standardized 3 T
MRI within 6 weeks before or after the baseline 7 T scan.
The 3 T scan included spinal cord MRI in four patients
(Table 3). No spinal cord lesions were detected (Table 3).
Follow-up 3 T MRI was performed in four patients –
after 12 months in patient #2, #4, #5, and after
18 months in patient #1 (Table 3). In these 4 patients, no
new lesions were detected at follow-up.
Evaluation of MS diagnostic panel criteria in
BCS patients
We investigated whether BCS patients fulfilled diagnosis
of MS as defined by the 2010 MS diagnostic panel crite-
ria.24 At study baseline, four of 10 BCS patients fulfilled
the 2010 MS diagnostic panel criteria (patient #1, #3, #6,
and #9, Table 3). In particular, all four patients fulfilled
the MRI criteria for dissemination in space. The MRI cri-
teria for dissemination in time were positive in three
patients (patients #1, #3, and #6). Clinical criteria for dis-
semination in time were positive in patients #3, #6, and
#9.
During the follow-up period, two of the four BCS
patients who met MS diagnostic criteria at baseline had
further relapses (patients #3 and #6). By contrast, no new
lesions or relapses were detectable in the BCS patients
who were initially negative with respect to MS diagnostic
criteria. In other words, none of these BCS patients met
MS diagnostic criteria during follow-up.
One limitation is that the assessment of the 2010 MRI
criteria for dissemination in time was not possible at
baseline in one BCS patient because no contrast agent
was given.
Histopathological findings in three BCS
patients
Brain biopsy and/or surgical resection was done prior to
this study in three BCS patients (Table 4). The biopsy
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decision was independently made by the treating center
specialized in neurology. Specimens of all three BCS
patients were characterized by demyelinating processes
with almost complete loss of myelin. Furthermore, a pre-
dominately T-cell–driven perivascular lymphocyte infiltra-
tion (n = 2) as well as activated microglia (n = 2),
astrogliosis with hypertrophic astrocytes (n = 2) and a
reduction of axonal density (n = 2) were regularly
observed within the lesion. While in one patient the
oligodendrocytes had enlarged nuclei, oligodendrocytes
were relatively well preserved in another. The axons in
one patient were predominantly preserved. In one patient,
astrocytes containing fragmented nuclei (Creutzfeldt–
Peters cells) were found.
Biomarkers in patients with Balo-type
lesions
Eight of 10 BCS patients had type 2 oligoclonal bands in
CSF but not in serum indicative of intrathecal IgG syn-
thesis (all three BCS patients with relapses; three of the
four BCS patients with positive 2010 MS diagnostic crite-
ria; Table 1).26 None of the BCS patients had antibodies
to AQP4 or MOG antibodies in serum.
Discussion
In this prospective ultrahigh-field MRI study we investi-
gated lesion characteristics in 10 BCS patients in compar-
ison to 10 typical RRMS patients without Balo-type
lesions. A central intralesional vein – characteristic for
MS lesions – was detectable within the majority of Balo-
type lesions, and a periventricular lesion distribution was
common in both disease types. In contrast to RRMS con-
trols, lesions in the cortical gray matter and subcortical
U-fibers were absent in all patients with BCS. Some
lesions in BCS patients were characterized by signs of
peripheral ectatic veins. In alignment with our in vivo
results, previous ex vivo investigations indicated that the
inflammation expands from a central venule into the sur-
rounding white matter in both MS- and BCS-derived
lesions.6,27 In contrast to MS, alternating patterns of
demyelination and preservation seem to proceed periodi-
cally in BCS, causing the characteristic large multilayer
lesions.7,19,20,28–30 However, the pathophysiologic under-
pinnings of this lesion pattern are currently not well
understood. Several mechanisms have been suggested,
including alternating gradients of proinflammatory and
anti-inflammatory agents, oxidative stress resulting in
Table 2. MRI findings – lesion morphology and localization in BCS and MS.
ID
Lesion number
(BCS: additional
lesions to BCS)
Central vein
(Balo lesions)
Central vein
(non-Balo lesions)
Dawson’s
fingers
Barkhof criteria
(brain MRI)
U-fiber
involvement
Cortical
lesions
BCS group
BCS #1 3 Yes 1 (33%) Yes No No No
BCS #2 4 Yes 2 (50%) No No No No
BCS #3 11 No 9 (82%) Yes Yes No No
BCS #4 0 N/A N/A No No No No
BCS #5 4 N/A 2 (50%) No No No No
BCS #6 62 Yes 14 (24%) No No No No
BCS #7 0 Yes N/A No No No No
BCS #8 3 Yes 1 (33%) Yes No No No
BCS #9 8 Yes 4 (50%) No No No No
BCS #10 2 Yes 2 (100%) No No No No
RRMS control group
RRMS #1 1 N/A 1 No No No No
RRMS #2 2 N/A 2 Yes No No No
RRMS #3 17 N/A 11 Yes Yes Yes No
RRMS #4 36 N/A 22 Yes Yes Yes No
RRMS #5 4 N/A 4 No No No 1
RRMS #6 40 N/A 33 Yes Yes Yes 5
RRMS #7 5 N/A 2 Yes No No No
RRMS #8 1 N/A 1 Yes No No No
RRMS #9 5 N/A 4 Yes No No No
RRMS #10 93 N/A 77 Yes Yes Yes No
BCS, Balo’s concentric sclerosis; MRI, magnetic resonance imaging; MS, multiple sclerosis; ID, identification number; RRMS, relapsing–remitting
MS; Barkhof criteria, >3/4 positive; Possible central vein was not detectable due to operation or biopsy (not applicable, n.a.).
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hypoxia-like tissue injury with a combination of protec-
tive and damaging factors, astrocytopathy as well as loss
of aquaporin 4 and connexin 43 which causes oligoden-
drocytopathy.1,2,19,30,31
In this study, an inhomogeneous intralesional T2*w sig-
nal intensity was observed in four of 10 Balo-type lesions,
which may be related to microhemorrhages or small ectatic
venous vessels within the lesions. Similar findings including
microhemorrhages and ectatic veins in T2w hyperintense
regions of a Balo-type lesion were previously described in a
7 T case report.32 The visibility of venous structures on
T2*w images of 7 T is dependent on the degree of deoxy-
genation of the venous blood, since only desoxyhe-
moglobine causes signal loss as a consequence of the
magnetic susceptibility effects.12 In line with previous MR
spectroscopy and diffusion-weighted MRI studies,7,32 these
imaging findings may reflect alterations in oxygen demand
and are in line with the hypothesis of hypoxia-induced
tissue degeneration during Balo-type lesion formation. In
addition, a potential overlap of BCS with other atypical
inflammatory demyelinating syndromes like tumefactive
demyelination as well as MOG-IgG- or AQP4-IgG-asso-
ciated brain damage has been proposed.3,33,34 In our study,
Creutzfeldt–Peters cells, a histopathological feature of
tumefactive demyelination, were detectable in one
biopsy.3,33 AQP4-IgG and MOG-IgG were negative in all
BCS patients, suggesting that these antibodies do not play a
key role in the pathogenesis of BCS.
Aside from these pathophysiological considerations
another key aspect of this study was to compare clinical
and paraclinical findings between patients with MS and
BCS. Similar to MS patients, our BCS patients often
exhibited positive oligoclonal bands (n = 8), Dawson’s
fingers (n = 3), and a visible central vein in 36 of 97
non-Balo lesions. While lesions that appeared to be typi-
cal MS lesions were also found in previous reports,4,5,9,20
Figure 2. Central intralesional vein in Balo concentric sclerosis. A distinct venous vessel is clearly visible within the center of the inner ring of one
exemplary Balo-type lesion on 7 T, T2*w (A), SWI (B) and MR phase images (C). 7 T, 7 Tesla; T2*w, two-dimensional T2*-weighted fast low-angle
shot (FLASH); SWI, three-dimensional gradient echo flow-compensated susceptibility-weighted imaging.
Figure 3. Inhomogeneous intralesional T2*w signal distribution within an exemplary Balo-type lesion. 7 T T2*w images of one exemplary lesion
(patient #7) are presented demonstrating T2* hypointense structures (arrows) within the lesion. These signal alterations potentially indicate
microhemorrhages or small ectatic venous vessels. 7 T, 7 Tesla; T2*w, two-dimensional T2*-weighted fast low-angle shot (FLASH).
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oligoclonal bands have been reported only in approxi-
mately two-thirds of BCS patients.5–7,35 Wallner-Blazek
et al. assumed the coexistence of MS-type lesions in
patients with atypical demyelinating lesions, including
Balo-type lesions, as an indicator of future disease
activity.9
Figure 4. MS-typical lesions in Balo concentric sclerosis. A T2*w image is displayed showing multiple MS-typical lesions (circle) with a central vein
in addition to a single but prominent Balo-type lesion (arrow). T2*w, two-dimensional T2*-weighted fast low-angle shot (FLASH); MS, multiple
sclerosis.
908 ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Balo Versus MS Lesion Morphology at 7 Tesla J. R. Behrens et al.
On this background, one might speculate that BCS is a
heterogeneous disease of which one subgroup shares com-
mon features with MS (oligoclonal bands, MS-type
lesions, relapses) while a different subgroup is character-
ized by a different etiopathogenesis. Our data is not con-
clusive on this issue: On one hand, three BCS patients
met the diagnostic criteria for MS at the onset of the
study, and two of these had further relapses. In addition,
all three BCS patients with a relapsing–remitting disease
course indeed exhibited additional non-Balo lesions with
a central vein, and two displayed positive oligoclonal
bands. On the other hand, we also observed similar find-
ings in the group without further relapses during the per-
iod of observation, and a recent systematic review did not
describe differences between BCS patients with and with-
out oligoclonal bands.35 Thus, a longer follow-up is
needed to ultimately determine the prognostic relevance
of a positive central vein sign, Dawson’s fingers, or oligo-
clonal bands in BCS.
One clear difference between BCS and RRMS controls,
however, was that in our study – in line with the litera-
ture (Table 5)4–7,18 – the majority of BCS patients showed
a stroke-like onset with relatively severe symptoms like
hemiparesis and hemihypesthesia.
Our study is not free from limitations. The small sam-
ple size and the short follow-up period in some patients
Table 3. 3 T MRI and clinical follow-up in patients with Balo concentric sclerosis.
ID
Baseline (MRI) Follow-up (MRI) Follow-up (clinical)
Follow-up
DiS DiT
Contrast
enhancement
Spinal
cord
lesions
MS
diagnosis
(MRI part
only)24
New
lesions
Spinal
lesions
MS
diagnosis
(MRI part
only)24
Follow-up
(months)
Disease course until end
of follow-up
MS diagnosis
(clinical and MRI
part combined)
#1 Yes Yes Asymptomatic N/A Yes No N/A Yes 34 No further relapses Yes
#2 Yes No No N/A No No N/A No 33 No further relapses No
#3 Yes Yes Yes No Yes N/A N/A N/A 38 Five relapses in total,
one relapse under
therapy
Yes
#4 Yes No No N/A No No N/A No 33 No further relapses No
#5 Yes No Symptomatic No No No No No 31 No further relapses No
#6 Yes Yes Asymptomatic N/A Yes N/A N/A N/A 31 Four relapses in total,
three relapses under
therapy
Yes
#7 No No No No No N/A N/A N/A 22 No further relapses No
#8 Yes No No No No N/A N/A N/A 21 No further relapses No
#9 Yes No N/A N/A N/A N/A N/A N/A 21 Two relapses, no
relapse
under therapy
Yes
#101 Yes No Symptomatic N/A No N/A N/A N/A 29 No further relapses No
ID, identification number; MRI, magnetic resonance imaging; N/A, not available; DiS, dissemination in space; DiT, dissemination in time; symp-
tomatic, contrast enhancement correlates with the clinical presentation; asymptomatic, contrast enhancement does not correlate with the clinical
presentation.
1Baseline data of patient ID 10 were derived from 7 T MRI. Follow-up: time between 7 T intervention and telephone interview.
Table 4. Histopathological findings in patients with Balo concentric
sclerosis.
ID Demyelination Histological characteristics Cell infiltration
#3 Sharply limited,
inactive
demyelination
Astrogliosis
Hypertrophic astrocytes
Activated microglia
Oligodendrocytes
with hypertrophic
nuclei in the
outlying areas
Reduced axons
T-cell dominating
and diffuse
infiltration
Plenty of
macrophages
#4 Limited
demyelination
Astroctopathy with
two or more nuclei
Astrocytopathy
surrounding the lesion
Axons relatively
well-preserved,
occasionally
hypertrophic
T-cells perivascular
#5 Demyelination
inside the
lesion
Astrogliosis
Hypertrophic astrocytes
Creutzfeldt–Peters cells
Activated microglia
Relatively well-preserved
oligodendrocytes inside
the lesion
Reduced axons
Lymphocytes
Plasma cells
Foamy
macrophages
ID, identification number.
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complicate the investigation of potential prognostic MR
biomarkers. Blinding to the BCS diagnosis was obviously
not fully achievable during MRI analysis, given the char-
acteristic brain lesions in BCS. Finally, various treatment
regimens most likely influenced clinical disease courses.
In summary, this is the first investigation of BCS
patients using ultrahigh-field MRI in a prospective obser-
vational study. We observed differences between Balo
patients and patients with RRMS, for instance, regarding
lesion location, involvement of cortical gray matter and
intralesional T2*w signal inhomogeneities. Nevertheless, a
central vein and Dawson’s fingers, which are both typical
of MS, were also present in some BCS patients. This sug-
gests that both diseases share at least some pathophysio-
logical commonalities. Although further prospective
studies are needed, our investigations show that BCS is
not necessarily a disease with a devastating prognosis.
Indeed, more than two-thirds of the BCS patients included
in our study had a clinically stable disease course without
further relapses during the time span that we covered.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information section at the end of the
article:
Figure S1. 7 T MR images at study onset. 7 T T2*w
images acquired at study onset of all patients with Balo
concentric sclerosis are presented. Each Balo-type lesion is
framed. BCS patients who underwent a biopsy are marked
with *. 7 T, 7 Tesla; T2*w, two-dimensional T2*-weighted
fast low-angle shot (FLASH).
Figure S2. MR images prior to surgical resection or
biopsy. The figure illustrates MR images that were
acquired prior to biopsy or surgical resection showing
contrast-enhancing Balo-type lesions in all three patients
(patients #3, #4, and #5). Key: (A) fluid-attenuated inver-
sion recovery (FLAIR) images; (B) T1w contrast-enhanced
images.
Figure S3. Lesion morphology of two exemplary Balo-
type lesions. While lesion (A) is characterized by rather
thin rims, lesion (B) exhibits a single thicker outer rim.
The relevance of such different lesion morphologies is
unknown yet. Please note the biopsy area in (A) (as-
terisk).
Figure S4. Intralesional T2*w and T1w gray-scale values
of Balo-type lesions. T2*w images (A and C) and T1w
images (B and D) of two patients with Balo-type lesions
are displayed. In general, Balo-type lesions were character-
ized by alternating layers of T2* hyperintense and hypoin-
tense layers. Hereby, T2*w hyperintense areas usually
correspond to strongly T1w hypointense areas (A and B).
In one patient (C and D), brain tissue in-between T2w
hyperintense rims appeared preserved (arrow in C and
D), given that it was characterized by T2*w and T1w
gray-scale intensity values similar to normal appearing
white matter. T2*w, two-dimensional T2*-weighted fast
low-angle shot (FLASH); T1w, three-dimensional T1-
weighted magnetization prepared rapid gradient echo
(MPRAGE).
Data S1. MR imaging acquisition of 3 T MRI sequences.
The MR imaging acquisition of the 3 T MRI sequences
(MPRAGE, T2-weighted images and FLAIR) are shown.
3 T, 3-Tesla MRI; MPRAGE, three-dimensional T1-
weighted magnetization prepared rapid gradient echo;
FLAIR, fluid-attenuated inversion recovery images.
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